BillionToOne CEO Liquidates Entire Directly-Held Stake in the Company for $3 Million
The medical diagnostics company disclosed a substantial insider stock sale.
Overview
Oguzhan Atay, Chairman and Chief Executive Officer of BillionToOne, Inc. (NASDAQ:BLLN), sold 30,331 shares of Class A Common Stock on September 14, 2026, for a total value of ~$3 million, as disclosed in a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($99.91); post-transaction value based on September 14, 2026 market close ($100.82).
Details
BillionToOne is a specialized diagnostics company with a market cap of $4.8 billion. The company's competitive advantage derives from its proprietary molecular counting platform, which enables precise quantification of individual DNA molecules to significantly enhance diagnostic accuracy.
Source
Originally published at www.fool.com.